Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Composition for treating hyperlipemia

A technology for hyperlipidemia and composition, applied in the field of composition containing niacin and atorvastatin calcium and pharmaceutical excipients

Inactive Publication Date: 2006-03-29
LUNAN PHARMA GROUP CORPORATION
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] Chinese patent application CN1425374A discloses a composition of niacin and lovastatin. The disclosed ratio is that the weight ratio of niacin and lovastatin is 25-50:1, and the preferred ratio is 25:1 or 37.5:1, but it does not involve Optimal ratio of niacin and atorvastatin compound and corresponding pharmacological experiment data

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating hyperlipemia

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0024] a. Niacin 600g

[0025] Blank ball core 250g

[0026] 7% PVP solution (solvent is 90% ethanol) 200g

[0027] Preparation process: Pass niacin through a 120-mesh sieve, weigh the prescribed amount, and pour it into the lower hopper. Turn on the granulation coating machine, the air inlet pressure is 0.5bar, the air inlet temperature is 30°C, the spray gun pressure (CYL) is 3bar, the atomization pressure (CAP1) is 0.8bar, pour blank ball cores, granulate, the feeding speed is 4rpm, the creeping Pump 12%, turntable speed 145rpm, spray 7% PVP solution (solvent is 90% ethanol). After granulation is completed, dry at 50°C and discharge.

[0028] b. Atorvastatin Calcium 5g

[0029] Blank ball core 30g

[0030] 7% PVP solution (solvent is 90% ethanol) 30g

[0031]Preparation process: pass atorvastatin calcium through a 120-mesh sieve, weigh the prescription amount, and pour it into the lower hopper. Start the granulation coating machine, the in...

example 2

[0034] a. Niacin 600g

[0035] Lactose 30g

[0036] Sodium carboxymethyl starch 30g

[0037] Microcrystalline Cellulose 18g

[0038] 6% PVP in absolute ethanol 100g

[0039] Magnesium Stearate 2g

[0040] Preparation process: Niacin is passed through a 100-mesh sieve, lactose, sodium carboxymethyl starch, and microcrystalline cellulose are passed through a 80-mesh sieve, and the prescribed amount of nicotinic acid is weighed and mixed with lactose, sodium carboxymethyl starch, and microcrystalline cellulose, Add an appropriate amount of 6% PVP absolute ethanol solution to granulate, dry at 60°C, sieve the dry granules with a 16-mesh sieve, and add the prescribed amount of magnesium stearate to the dry granules.

[0041] b. Atorvastatin calcium 10g

[0042] Hydroxypropyl Cellulose 15g

[0043] 10g pregelatinized starch

[0044] 6% PVP in absolute ethanol solution 30g

[0045] Glyceryl Behenate 1g

[0046] P...

example 3

[0049] a. Niacin 600g

[0050] Lactose 30g

[0051] Sodium carboxymethyl starch 30g

[0052] Microcrystalline Cellulose 18g

[0053] 6% PVP in absolute ethanol 100g

[0054] Magnesium Stearate 2g

[0055] Preparation process: Niacin is passed through a 100-mesh sieve, lactose, sodium carboxymethyl starch, and microcrystalline cellulose are passed through a 80-mesh sieve, and the prescribed amount of nicotinic acid is weighed and mixed with lactose, sodium carboxymethyl starch, and microcrystalline cellulose, Add an appropriate amount of 6% PVP absolute ethanol solution to granulate, dry at 60°C, sieve the dry granules with a 16-mesh sieve, and add the prescribed amount of magnesium stearate to the dry granules.

[0056] b. Atorvastatin calcium 20g

[0057] Hydroxypropyl Cellulose 30g

[0058] 20g pregelatinized starch

[0059] 6% PVP in absolute ethanol solution 50g

[0060] Glyceryl Behenate 2g

[0061] P...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel composition for treating hyperlipemia, which comprises effective dose of Nicotinic Acid and Atorvastatin calcium by the weight ratio is (30-240) : 1.

Description

Technical field [0001] The invention relates to a new composition for treating hyperlipidemia, especially a composition containing niacin, atorvastatin calcium and pharmaceutical auxiliary materials. Background technique [0002] With the continuous development of medical science, people realize that the high content of cholesterol and fat is the basic cause of cardiovascular disease, and hyperlipidemia is the main risk factor of coronary heart disease and hypertension. Therefore, people began to focus on the development of blood lipid regulating drugs as the prevention and treatment of cardiovascular diseases. Since the late 1980s, a large number of blood lipid-lowering drugs have been launched, among which statins have been well received by people, and their clinical efficacy is unmatched by other types of blood lipid regulating drugs. Over the past ten years, the completion of several international large-scale coronary heart disease prevention and treatment trials has co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/455A61P3/06A61K31/40
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products